The present study aimed to characterize IL-6/IL-10 trajectories and determine the predictive efficacy of the DBS for clinical outcomes in hospitalized COVID-19 patients, benchmarking it against WHO-CPS and IL-6 as a standalone biomarker. This evidence concerns the gene IL10 and COVID-19.